Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ixabepilone,Capecitabine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Vector Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East
Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.
Product Name : Ixempra
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 22, 2021
Lead Product(s) : Ixabepilone,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Vector Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Olokizumab
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : UCB Pharma S.A
Deal Size : Inapplicable
Deal Type : Inapplicable
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 15, 2012
Lead Product(s) : Olokizumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : UCB Pharma S.A
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olokizumab
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : UCB Pharma S.A
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 15, 2011
Lead Product(s) : Olokizumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : UCB Pharma S.A
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
